Drug Profile
Filgrastim biosimilar - Profarma
Alternative Names: PF-07Latest Information Update: 12 Nov 2021
Price :
$50
*
At a glance
- Originator Profarma
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for preclinical development in Cancer in Lithuania
- 15 Jun 2015 Preclinical trials in Cancer in Lithuania (unspecified route) (Profarma pipeline, June 2015)
- 02 Apr 2015 Profarma has patent protection for filgrastim biosimilar (Profarma website, June 2015) before April 2015